MX2020003753A - Composicion nasal de vacuna contra hepatitis b y metodo para producir la misma. - Google Patents

Composicion nasal de vacuna contra hepatitis b y metodo para producir la misma.

Info

Publication number
MX2020003753A
MX2020003753A MX2020003753A MX2020003753A MX2020003753A MX 2020003753 A MX2020003753 A MX 2020003753A MX 2020003753 A MX2020003753 A MX 2020003753A MX 2020003753 A MX2020003753 A MX 2020003753A MX 2020003753 A MX2020003753 A MX 2020003753A
Authority
MX
Mexico
Prior art keywords
hepatitis
vaccine composition
producing same
nasal
nasal hepatitis
Prior art date
Application number
MX2020003753A
Other languages
English (en)
Inventor
Taizou Kamishita
Takashi Miyazaki
Michinori Kohara
Takahiro Sanada
Yoichi Hiasa
Osamu Yoshida
Kyoko Kohara
Hideki Hasegawa
Original Assignee
Toko Yakuhin Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toko Yakuhin Kogyo Kk filed Critical Toko Yakuhin Kogyo Kk
Publication of MX2020003753A publication Critical patent/MX2020003753A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

La presente invención se relaciona con una composición para vacuna contra hepatitis B para administración por atomización a la mucosa nasal para prevenir y tratar la hepatitis B, que comprende un antígeno de hepatitis B y un polímero de carboxi vinilo.
MX2020003753A 2017-10-05 2018-10-04 Composicion nasal de vacuna contra hepatitis b y metodo para producir la misma. MX2020003753A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017195262 2017-10-05
PCT/JP2018/037172 WO2019070019A1 (ja) 2017-10-05 2018-10-04 経鼻ｂ型肝炎ワクチン組成物およびその製造方法

Publications (1)

Publication Number Publication Date
MX2020003753A true MX2020003753A (es) 2020-11-09

Family

ID=65994315

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003753A MX2020003753A (es) 2017-10-05 2018-10-04 Composicion nasal de vacuna contra hepatitis b y metodo para producir la misma.

Country Status (14)

Country Link
US (1) US11491219B2 (es)
EP (1) EP3693006A4 (es)
JP (2) JPWO2019070019A1 (es)
KR (1) KR20200071742A (es)
CN (1) CN111344005A (es)
AU (1) AU2018345493A1 (es)
BR (1) BR112020005695A2 (es)
CA (1) CA3075423A1 (es)
IL (1) IL273168B1 (es)
MX (1) MX2020003753A (es)
PH (1) PH12020550211A1 (es)
SG (1) SG11202002281YA (es)
TW (1) TWI811248B (es)
WO (1) WO2019070019A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024048570A1 (ja) * 2022-08-30 2024-03-07 国立大学法人愛媛大学 経鼻投与用ｂ型肝炎ワクチン組成物および該ワクチン組成物の経鼻投与システム

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158761A (en) * 1989-04-05 1992-10-27 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
CN1171636C (zh) * 2001-06-06 2004-10-20 中国人民解放军第二军医大学 一种乙型肝炎dna疫苗
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
CU23405A1 (es) 2003-10-20 2009-08-04 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas para uso terapéutico
SI2011467T1 (sl) 2006-04-21 2021-01-29 Toko Yakuhin Kogyo Kabushiki Kaisha Posoda za tekočino in brezzračni sistem za razdeljevanje tekočine
HUE036777T2 (hu) * 2006-04-21 2018-07-30 Toko Yakuhin Kogyo Kk Bõrhöz/nyálkahártyához tapadó porlasztható gél típusú preparátum és adagolási rendszer a preparátum alkalmazásával
CN110038123A (zh) * 2012-12-28 2019-07-23 日本国立感染症研究所 经鼻流感疫苗组合物
JP6322844B2 (ja) 2014-06-25 2018-05-16 東興薬品工業株式会社 医療用シリンジに用いられる点鼻用噴霧ノズル

Also Published As

Publication number Publication date
WO2019070019A1 (ja) 2019-04-11
SG11202002281YA (en) 2020-04-29
IL273168A (en) 2020-04-30
BR112020005695A2 (pt) 2020-10-06
US20200261568A1 (en) 2020-08-20
CN111344005A (zh) 2020-06-26
PH12020550211A1 (en) 2021-02-15
TW201922226A (zh) 2019-06-16
US11491219B2 (en) 2022-11-08
JP2023012539A (ja) 2023-01-25
KR20200071742A (ko) 2020-06-19
EP3693006A4 (en) 2021-07-07
JPWO2019070019A1 (ja) 2020-10-22
AU2018345493A1 (en) 2020-04-02
TWI811248B (zh) 2023-08-11
EP3693006A1 (en) 2020-08-12
RU2020115051A (ru) 2021-11-08
IL273168B1 (en) 2024-03-01
CA3075423A1 (en) 2019-04-11
RU2020115051A3 (es) 2021-11-18

Similar Documents

Publication Publication Date Title
CY1124033T1 (el) Δοσολογια και χορηγηση μη φουκοζυλιωμενων αντισωματων anti-cd40
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
WO2018115527A3 (en) Mers coronavirus vaccine
NI201800052A (es) Anticuerpos que neutraliza el virus respiratorio sincitial humano
MX2018013504A (es) Metodos de fabricacion, composiciones y aplicaciones medicas de productos farmaceuticos de cannabis administrables oralmente.
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
PH12016500486A1 (en) Aza-pyridone compounds and uses thereof
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
CL2018000811A1 (es) Formulaciones de aminoácidos de liberación modificada administradas por vía oral.
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
PH12018500254A1 (en) Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
UA116697C2 (uk) Композиція для запобігання зараженню видами роду mycoplasma
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
AU2015352158A8 (en) Medicaments for slowing Parkinson's Disease
BR112017014598A2 (pt) métodos e usos para hidrólise de queratina
BR112017000022A2 (pt) nanoparticulas terapêuticas direcionadas a alvo e métodos de produção e uso dessas partículas
CY1125031T1 (el) Μεθοδος για γενετικη θεραπεια χρησιμοποιωντας τον ιο aav-xbp1s/gfp και χρηση αυτης στην προληψη και τη θεραπεια της αμυοτροφικης πλευρικης σκληρυνσης
BR112017028224A2 (pt) composição, e, método para proteger um leitão contra uma doença associada a pestivírus.
MX2020003753A (es) Composicion nasal de vacuna contra hepatitis b y metodo para producir la misma.
MX2017015004A (es) Estrategia de vacuna basada en nanoparticulas contra el virus de la influenza porcina.
BR112017012938A2 (pt) uso por via oral de uma composição e método para aprimorar a aparência da celulite
NI201800105A (es) Anticuerpos, composiciones y antígenos de chaga, métodos y usos de los mismos.
IN2013MU03428A (es)
CY1119636T1 (el) Φαρμακευτικο παρασκευασμα με βαση διοσμεκτιτη